Biome Australia (BIO) H2 2025 earnings summary

Executive summary

• Achieved first full year of net profit since founding in 2018, with FY25 net profit of $214,656 and sales revenue of $18.42 million, up 41.6% year-over-year.

• Maintained strong gross margin of 61.1% and positive EBITDA for six consecutive quarters (excluding share-based payments), with full-year EBITDA exceeding $931,050.

• Domestic sell-through increased by over 50%, securing the #2 position in total probiotic revenue within community pharmacy.

• International sales grew 69% to $1.5 million, with new distribution partnerships in Canada, Ireland, UK, and New Zealand.

• Launched new practitioner-only range, Activated Therapeutics, and completed proprietary probiotic strain development (BMB18).

Financial highlights

• Sales revenue: $18,417,188 in FY25, up from $13,008,897 in FY24 (41.6% growth).

• Net profit: $214,656 in FY25, compared to a loss of $1,670,202 in FY24.

• Gross profit: $11,256,288 (gross margin 61.1%).

• EBITDA (excluding share-based payments): over $931,050 for FY25.

• Cash position: $2,746,416 at 30 June 2025, with an undrawn $2,094,587 credit facility.

• Compound annual growth rate (CAGR) of 64.7% for the three years ending 30 June 2025.

Outlook and guidance

• Entered FY26 with an annualised sales revenue run rate exceeding $20 million.

• Vision 27 strategic plan targets $75–$85 million cumulative revenue over FY25–27.

• International expansion and new product launches expected to drive further growth.